Various HDAC inhibitors listed in Table 3, such as Entinostat (MS-275) and Panobinostat (LBH589), are currently undergoing clinical trials for a range of cancers, including breast cancer, non-small cell lung cancer, and leukemia, demonstrating their broad therapeutic potential. This evidence concerns the gene HDAC9 and cancer.